PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7638751-7 1995 RESULTS: Lipopolysaccharide or zymosan-activated macrophages in coculture with IEC secreted significantly less TNF-alpha than macrophages cultured alone. Zymosan 31-38 tumor necrosis factor Rattus norvegicus 111-120 8777270-0 1996 Resident joint tissues, rather than infiltrating neutrophils and monocytes, are the predominant sources of TNF-alpha in zymosan-induced arthritis. Zymosan 120-127 tumor necrosis factor Rattus norvegicus 107-116 8777270-1 1996 Intraarticular injection of zymosan (1 mg) into the knee joints of male Wistar rats led to infiltration of neutrophils and monocytes, joint swelling and elevation of tumour necrosis factor (TNF-alpha) in joint lavage fluids. Zymosan 28-35 tumor necrosis factor Rattus norvegicus 190-199 8777270-6 1996 These data indicate that in zymosan-induced arthritis TNF-alpha is produced from the resident joint tissues such as the synovial lining cells rather than infiltrating neutrophils or monocytes. Zymosan 28-35 tumor necrosis factor Rattus norvegicus 54-63 1329867-6 1992 The reverse was found for zymosan-induced TNF-alpha production, which was higher in AM from silica-exposed than from control rats. Zymosan 26-33 tumor necrosis factor Rattus norvegicus 42-51 7757523-5 1994 Stimulation of LPS- and TNF-treated PMN with phorbol 12-myristate 13-acetate (PMA), opsonized zymosan (OPZ), and anti-rat CD11b/c MAb triggered O2- generation. Zymosan 94-101 tumor necrosis factor Rattus norvegicus 24-27 7552773-4 1995 Zymosan increased the plasma concentration of TNF alpha, and this was associated with a decrease (approximately 40%) in the IGF-I concentration in plasma, liver, heart, and brain. Zymosan 0-7 tumor necrosis factor Rattus norvegicus 46-55 7552773-10 1995 We conclude that zymosan-induced inflammation not only decreases IGF-I in plasma and selected tissues, but also increases IGFBP-1 in plasma, liver, and muscle, and that these alterations are due in large part to the enhanced production of TNF alpha. Zymosan 17-24 tumor necrosis factor Rattus norvegicus 239-248 1329867-8 1992 VZ 65 suppressed zymosan-induced TNF-alpha release from AM in a dose-dependent manner, and TNF-alpha production could be restored almost completely by addition of LTB4. Zymosan 17-24 tumor necrosis factor Rattus norvegicus 33-42 2558582-4 1989 In contrast, rTNF alpha, in a dose-dependent manner, primed neutrophils for HOCl production in response to the weak agent unopsonized zymosan. Zymosan 134-141 tumor necrosis factor Rattus norvegicus 13-23 1898344-8 1991 The activity of the HMS in response to zymosan was increased by 400% after TNF treatment. Zymosan 39-46 tumor necrosis factor Rattus norvegicus 75-78 1898344-11 1991 Zymosan, however, increased HMS activity only in endothelial cells from TNF-treated rats. Zymosan 0-7 tumor necrosis factor Rattus norvegicus 72-75 1650523-4 1991 Injection of zymosan into the airpouch caused a time-dependent stimulation of TNF production which preceded leukotriene generation by at least 30 minutes. Zymosan 13-20 tumor necrosis factor Rattus norvegicus 78-81 18983578-12 2008 Serum TNF-alpha levels in dams exposed to zymosan and in their offspring at 56 weeks of age (but not at 24 weeks of age) were significantly increased compared with levels in the control group. Zymosan 42-49 tumor necrosis factor Rattus norvegicus 6-15 25819555-9 2015 Together, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-alpha, IL-1beta, and IL-6, but does not depend on either CRF or ET-1. Zymosan 68-75 tumor necrosis factor Rattus norvegicus 154-163 24651990-1 2014 This study compared the involvement of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) within the central nervous system (CNS) in the febrile response induced by zymosan (zym) and lipopolysaccharide (LPS). Zymosan 194-201 tumor necrosis factor Rattus norvegicus 79-106 24651990-1 2014 This study compared the involvement of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) within the central nervous system (CNS) in the febrile response induced by zymosan (zym) and lipopolysaccharide (LPS). Zymosan 194-201 tumor necrosis factor Rattus norvegicus 108-117 24651990-1 2014 This study compared the involvement of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) within the central nervous system (CNS) in the febrile response induced by zymosan (zym) and lipopolysaccharide (LPS). Zymosan 194-197 tumor necrosis factor Rattus norvegicus 79-106 24651990-1 2014 This study compared the involvement of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) within the central nervous system (CNS) in the febrile response induced by zymosan (zym) and lipopolysaccharide (LPS). Zymosan 194-197 tumor necrosis factor Rattus norvegicus 108-117 20646933-5 2010 Ulinastatin treatment significantly decreased the zymosan-induced elevation in serum concentrations of TNF-alpha and sICAM-1 and tissue abundance of TLR mRNA in the liver, kidney and lung, effectively attenuated the development of the polysaccharide-induced biochemical and histological abnormalities and successfully reduced the MODS-associated death. Zymosan 50-57 tumor necrosis factor Rattus norvegicus 103-112 28587937-0 2017 Anti-inflammatory and anti-nociceptive effects of strontium ranelate on the zymosan-induced temporomandibular joint inflammatory hypernociception in rats depend on TNF-alpha inhibition. Zymosan 76-83 tumor necrosis factor Rattus norvegicus 164-173 27344040-0 2016 Lectin from Abelmoschus esculentus reduces zymosan-induced temporomandibular joint inflammatory hypernociception in rats via heme oxygenase-1 pathway integrity and tnf-alpha and il-1beta suppression. Zymosan 43-50 tumor necrosis factor Rattus norvegicus 164-173 21445588-3 2011 CMIT markedly inhibited phagocytic oxidative burst as measured by zymosan-induced chemiluminescence, and cellular cytokine secretion as measured by zymosan-induced TNF-alpha secretion. Zymosan 148-155 tumor necrosis factor Rattus norvegicus 164-173 18983578-14 2008 of adult rat offspring at 24 weeks of age, there was a further increase in serum TNF-alpha levels in offspring in the zymosan-treated group compared with the other two groups. Zymosan 118-125 tumor necrosis factor Rattus norvegicus 81-90 16797904-7 2006 Moreover, zymosan treated aged rats showed 142% and 64% greater increase in pulmonary alveolar macrophages (AMs) apoptotic rate and serum TNF-alpha level, respectively, whereas 43% smaller increase in serum IL-10 level compared to zymosan treated adult rats. Zymosan 10-17 tumor necrosis factor Rattus norvegicus 138-147 16864404-12 2006 Zymosan treatment increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-10, and IL-12p70 secretion in BALF on day 1. Zymosan 0-7 tumor necrosis factor Rattus norvegicus 28-61 16597438-4 2006 The expression of TNF-alpha, determined by immunohistochemical staining, in synovial tissues obtained from articular joints injected with zymosan was also inhibited by thalidomide pretreatment. Zymosan 138-145 tumor necrosis factor Rattus norvegicus 18-27 16597438-3 2006 Furthermore, thalidomide pretreatment significantly reduced the concentration of tumor necrosis factor-alpha (TNF-alpha, -68.4%) in the exudate of zymosan-injected joints, but not those of interleukin-1beta, interleukin-6, CINC-1 or interleukin-10. Zymosan 147-154 tumor necrosis factor Rattus norvegicus 81-108 16597438-3 2006 Furthermore, thalidomide pretreatment significantly reduced the concentration of tumor necrosis factor-alpha (TNF-alpha, -68.4%) in the exudate of zymosan-injected joints, but not those of interleukin-1beta, interleukin-6, CINC-1 or interleukin-10. Zymosan 147-154 tumor necrosis factor Rattus norvegicus 110-119 12813363-10 2003 Administration of PAF-AH significantly inhibited LPS-induced tumor necrosis factor alpha and interleukin-1beta production by alveolar macrophages from zymosan-treated animals. Zymosan 151-158 tumor necrosis factor Rattus norvegicus 61-88 15550091-5 2004 The production of TNF-alpha, interleukin (IL)-1beta, IL-6, and IL-10 was assessed after 4, 12 and 24 h. RESULTS: Lipopolysaccharide and zymosan stimulated TNF-alpha, IL-1beta, and IL-10 production; and peritoneal fluids from both control animals and animals with zymosan-induced peritonitis stimulated the production of TNF-alpha, IL-1RII, and IL-6. Zymosan 136-143 tumor necrosis factor Rattus norvegicus 155-164 15550091-5 2004 The production of TNF-alpha, interleukin (IL)-1beta, IL-6, and IL-10 was assessed after 4, 12 and 24 h. RESULTS: Lipopolysaccharide and zymosan stimulated TNF-alpha, IL-1beta, and IL-10 production; and peritoneal fluids from both control animals and animals with zymosan-induced peritonitis stimulated the production of TNF-alpha, IL-1RII, and IL-6. Zymosan 136-143 tumor necrosis factor Rattus norvegicus 155-164 11504783-3 2001 Oral administration of GW3333 completely blocked increases in plasma TNF after LPS for up to 12 h. In a model wherein intrapleural zymosan injection causes an increase in TNF in the pleural cavity, GW3333 completely inhibited the increase in TNF in the pleural cavity for 12 h. Under these dosing conditions, the plasma levels of unbound GW3333 were at least 50-fold above the IC(50) values for inhibition of individual MMPs in vitro. Zymosan 131-138 tumor necrosis factor Rattus norvegicus 171-174 11708926-6 2001 One inhibitor, 28a, with roughly 10x selectivity over MMP1 and MMP3 and high solubility in SGF, was evaluated in the rat zymosan-induced pleuisy model of inflammation and found to inhibit zymosan-stimulated pleural TNF-alpha elevation by 30%. Zymosan 188-195 tumor necrosis factor Rattus norvegicus 215-224 11858733-4 2002 Treatment with zymosan on Day 1 and LPS on Day 2 modified several indices of pulmonary responsiveness, including tumor necrosis factor-alpha, albumin, and lactate dehydrogenase activity (LDH) in first acellular lavage fluid as well as the levels of chemiluminescence (CL), NO-dependent CL, and nitric oxide production in cultured lavaged alveolar macrophage cells determined 1 day after exposure. Zymosan 15-22 tumor necrosis factor Rattus norvegicus 113-140 11504783-3 2001 Oral administration of GW3333 completely blocked increases in plasma TNF after LPS for up to 12 h. In a model wherein intrapleural zymosan injection causes an increase in TNF in the pleural cavity, GW3333 completely inhibited the increase in TNF in the pleural cavity for 12 h. Under these dosing conditions, the plasma levels of unbound GW3333 were at least 50-fold above the IC(50) values for inhibition of individual MMPs in vitro. Zymosan 131-138 tumor necrosis factor Rattus norvegicus 171-174 10049519-0 1998 Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo. Zymosan 40-47 tumor necrosis factor Rattus norvegicus 74-77 10049519-5 1998 These results suggest that CINC produced in the pleural exudate may participate in neutrophil infiltration, that IL-6 induced in the plasma stimulates T-kininogen production, and that endogenous TNF may be partly involved in the induction of CINC and IL-6 in this zymosan inflammation. Zymosan 264-271 tumor necrosis factor Rattus norvegicus 195-198 9875906-12 1998 Zymosan determined a time-dependent increase in peritoneal, plasma NOx, and tumor necrosis factor (TNF)-alpha concentrations. Zymosan 0-7 tumor necrosis factor Rattus norvegicus 76-109 9875906-15 1998 Moreover, TNF-alpha levels were significantly reduced in animals shocked by zymosan and treated with HBO. Zymosan 76-83 tumor necrosis factor Rattus norvegicus 10-19